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Abstract
Purpose AMPK plays a crucial role in the regulation of the
energy metabolism of the heart. During ischaemia, AMPK
activation is a known adaptative prosurvival mechanism
that helps to maintain the energy levels of the myocardium.
However, it still remains unclear if activation of AMPK
during reperfusion is beneficial for the heart. Two known
AMPK activators (metformin and AICAR) were used to
verify the hypothesis that a transitory activation of AMPK
at reperfusion may exert cardioprotection, as reflected in a
reduction in myocardial infarct size.
Methods Perfused rat hearts were subjected to 35 min
ischaemia and 120 min reperfusion. Metformin (50 μM) or
AICAR (0.5 mM) were added for 15 min at the onset of
reperfusion alone or with Compound C (CC, 10 μM), an
AMPK inhibitor. Infarct size and α-AMPK phosphoryla-
tion were measured.
Results Metformin significantly reduced infarct size from
47.8±1.7% in control to 31.4±2.9%, an effect abolished by
CC when the drugs were given concomitantly. Similarly,
AICAR also induced a significant reduction in infarct size
to 32.3±4.8%, an effect also abrogated by CC. However,
metformin’s protection was not abolished if CC was
administered later in reperfusion. In addition, α-AMPK
phosphorylation was significantly increased in the metfor-
min treated group during the initial 30 min of reperfusion.
Conclusions Our data demonstrated that, in our ex vivo
model of myocardial ischaemia-reperfusion injury, AMPK
activation in early reperfusion is associated with a reduction
in infarct size.
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Introduction
5′-AMP-activated kinase (AMPK) is an heterotrimeric
protein that acts as an intracellular energy sensor [1].
AMPK is activated by a variety of stresses such as glucose
deprivation, exercise, hypoxia, oxidative stress and ischae-
mia which either increase energy demand beyond normal
rates or impair energy production, thus resulting in an
increase of the ratio of AMP/ATP to which AMPK is
sensitive to. Upon activation, AMPK enhances catabolic
pathways that increase ATP levels, such as glycolysis and
fatty acid oxidation as well as inhibits ATP-consuming
pathways, by phosphorylating several key enzymes of
metabolic pathways such as glucose and fatty acid
metabolism, as well as protein synthesis [2, 3]. Therefore
AMPK is able to coordinate not only intracellular signal-
ling, but also the metabolism and the gene expression in
cells and, in addition, is thought to have a crucial role in
whole body insulin sensitivity [4].
AMPK is particularly relevant in tissues with high
energetic demands such as the neuronal tissue and cardiac
muscle. Cardiac AMPK is known to be activated during
ischaemia, when ATP production via oxidative phosphor-
ylation is reduced due to the diminished oxygen and
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nutrient supply [5]. However, prolonged glycolysis may be
detrimental due to accumulation of harmful products such
as lactic acid and protons, which are eliminated by
mechanisms that consume energy [5]. Therefore, it is yet
to be clarified as to whether the activation of AMPK during
the first minutes of reperfusion following a period of
ischaemia is beneficial or harmful to the heart.
AMPK activity may be modulated by hormones (leptin,
adipocytokynes) or by pharmacological agents such as
AICAR, thiazolidenediones and metformin, amongst sev-
eral others [3]. We used metformin and AICAR, which are
nonrelated chemical activators of AMPK. AICAR (5-
amino-4-imidazolecarboxamide-riboside) is an adenosine
analogue that is taken up by adenosine transporters and
further phosphorylated to ZMP, thus mimicking AMP in the
activation process of AMPK [6].
Metformin is a worldwide pharmacological agent used in
the treatment of type 2 diabetes which precise mechanism
of action is not very well known in spite of its clinical use
[7]. Although metformin is known to activate AMPK [8],
the exact mechanism remains to be elucidated. It is thought
that metformin indirectly activates AMPK by inhibiting
complex I from the mitochondrial respiratory chain, thus
decreasing the levels of ATP and increasing accumulation
of intracellular AMP [9]. Importantly, both metformin [10–
13] and AICAR were shown to reduce myocardial
ischaemia-reperfusion injury [14].
In the present study we used a model of ex-vivo
myocardial ischaemia-reperfusion injury and two different
AMPK activators (metformin and AICAR), to investigate if
a transitory activation of AMPK at the onset of reperfusion
could be beneficial for the heart and thus play a significant
role in the observed cardioprotection.
Methods
Materials
Metformin (Sigma, UK) and AICAR (5-amino-4-imidazo-
lecarboxamide-riboside), (Toronto Research Chemicals,
Canada) were dissolved in water. Compound C (6-[4-(2-
Piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-
a]-pyrimidine, blocker of AMPK activity) (Sigma, UK) was
dissolved in dimethyl sulphoxide (DMSO) and diluted into
buffer such that the final concentration of the vehicle did
not exceed 0.1% of the total volume. All other reagents
were of standard analytical grade.
Animal model
Male Wistar rats were obtained from Charles River
(Margate, UK) and were treated in accordance with the
United Kingdom Animals (Scientific Procedures) Act of
1986 (The Stationery Office, London, UK). The investi-
gation conforms to the Guide for the Use of Laboratory
Animals published by the US National Institutes of
Health (NIH Publication No.85-23, revised 1996). A
total of 103 animals were used during this research
study.
Langendorff-perfused rat heart studies
Male Wistar rats (350–400 g) were anaesthetised with
sodium pentobarbital (55 mg/kg, ip) and heparin (300 IU).
The hearts were quickly excised and mounted onto a
Langendorff constant pressure system (ADInstruments).
They were perfused with oxygenated Krebs–Henseleit
buffer (118 mM NaCl, 25 mM NaHCO3, 11 mM Glucose,
4.7 mM KCl, 1.22 mM MgSO4.7H2O, 1.21 mM KH2PO4
and 1.84 mM CaCl2.2H2O) and kept at 37°C throughout
the experiment, according to the method described previ-
ously [15]. An intraventricular balloon was used to
permanently monitor the heart function (heart rate = HR,
left ventricular developed pressure = LVDP, and to
calculate Rate Pressure Product = RPP). The hearts were
subjected to 35 min of regional ischaemia with the help of a
snare, which temporarily obstructed the left anterior
descending coronary artery, after which the ligature was
released and the ischaemic zone was reperfused for
120 min. At the end of this period the snare was tightened
and Evans blue (0.25% in saline) was slowly infused via
the aortic root in order to delineate the myocardial tissue
which was not at risk (blue). Hearts were then frozen at
−20°C for several hours before being sliced into 2 mm
thick transverse sections and incubated with triphenylte-
trazolium chloride (TTC; 1% in phosphate buffer). TTC
reacts with intracellular dehydrogenases to stain viable
tissue red leaving the infarcted areas off-white. The slices
were transferred to 10% formalin overnight and subse-
quently drawn onto acetate. Computerized planimetry
(Suma Sketch III, Summagraphics, Seymour, CT) was used
to measure the percentage of infarcted tissue within the risk
zone (I/R%). The hearts were randomly assigned to one of
the following treatment groups (n≥6 per group; see Fig. 1).
All treatments were applied for the first 15 min of
reperfusion:
(1) Control hearts either received 0.1% DMSO (vehicle
control n=8) or Krebs-Henseleit buffer alone (n=8);
(2) Metformin: hearts were given metformin (50 μM) (n=
10); [16]
(3) Metformin + Compound C given simultaneously:
hearts were perfused with both 50 μM of metformin
and 10 μM of compound C (dissolved in 0.1% DMSO)
(n=8);
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(4) Metformin + delayed Compound C: hearts were
perfused with metformin from the onset of reperfusion
and compound C was added 5 min later than
metformin for 10 min (n=6);
(5) Delayed compound C: hearts were administered
10 μM of compound C, between 5 and 15 min of
reperfusion (n=7);
(6) AICAR: hearts were perfused with 0.5 mM AICAR
(n=8);
(7) AICAR + Compound C: hearts were perfused with
both 0.5 mM of AICAR and 10 μM of compound C
(n=7);
(8) Compound C alone: hearts were administered 10 μM
of compound C (n=7) [17].
Exclusions
A number of 11 experiments were excluded from the study.
The exclusion criteria were: more than 3 min delay between
the harvesting of the heart and the mounting of the isolated
heart in the Langendorff system, poor cardiac function
during stabilization (RPP less than 17,000 mmHg min−1),
or occurrence of severe ventricular fibrillation.
Western blot analysis
Hearts excised from male Wistar rats were Langendorff-
perfused as described above and were subjected to 35 min
of regional ischaemia followed by 30 min of reperfusion
with or without metformin for the first 15 min of
reperfusion. Samples taken from the area-at-risk, at differ-
ent time points (respectively 40 min of stabilization, 30 min
of ischaemia and 3, 7, 15 and 30 min of reperfusion), were
snap-frozen in liquid nitrogen for subsequent Western blot
analysis of the α-AMPK phosphorylation (N=3 per group),
as outlined in Fig. 1.
Proteins were extracted by homogenization and centri-
fugation in cold suspension buffer containing: 100 mM
NaCl, 10 mM Tris (pH 7.6), 1 mM EDTA (pH 8), 2 mM
sodium pyrophosphate, 2 mM sodium fluoride, 2 mM β-
glycerophosphate, protease cocktail and 0.5 mM 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride
(AEBSF). Protein content was determined using bicincho-
ninic acid (BCA) reagent (Sigma, UK). Furthermore,
samples were denatured by heating to 95°C for 10 min in
sample buffer, which contained: l00 mM Tris (pH 6.8),
200 mM DTT, 2% SDS, 0.2% Bromophenol blue and 20%
Glycerol.
Western blot analysis was performed as previously
described [18]. Briefly, 30 μg of protein were loaded on
each well onto a 12.5% SDS-PAGE gel and subsequently
transferred onto a Hybond ECL nitrocellulose membrane
(Amersham, UK). Adequate transfer of proteins was
confirmed by Ponceau Red (Sigma, UK) staining of the
membrane.
The membranes were probed with polyclonal antibodies
(1:1000) for phospho-α-AMPK (Thr172) and total α-
AMPK and were used in accordance with the manufacter’s
instructions (Cell Signaling, New England Biolabs, UK).
The membranes were then probed with horseradish perox-
idase conjugated anti-rabbit antibody (1:1000). Proteins
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Fig. 1 Experimental protocols.
Hearts were randomly assigned
to the following groups (1)
Control hearts; (2) Metformin;
(3) Metformin + CC; (4) Met-
formin + delayed CC ;(5)
Delayed compound C; (6)
AICAR; (7) AICAR + CC ; (8)
Compound C. All drug treat-
ments were applied 5 min before
the onset of reperfusion, with
the exception of CC in groups 4
and 5 which was administered
after 15 min of reperfusion.
Western blot samples were col-
lected at several time points
(40 min of stabilization, 30 min
of ischaemia, 3, 7, 15 and
30 min reperfusion) for groups 1
and 2
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were visualized by enhanced chemiluminescence (ECL,
Amersham, UK) and quantified by densitometry using NHI
Image 1.63. For subsequent re-probing the membranes
were submersed in stripping buffer (Pierce, UK) for 15 min
followed by thorough washing in order to remove the
antibodies. This enabled re-probing with β-actin (AbCam,
UK), necessary to normalise the signals of interest to the
protein loading.
Statistical analysis
Data were statistically analysed by one-way ANOVA,
followed by a Newman-Keuls post test using GraphPad
Prism 5.0 (GraphPad Software Inc, San Diego, California,
USA). A P-value <0.05 was considered to be statistically
significant. Values are presented as means ± standard error
mean (SEM).
Results
Haemodynamic data
The baseline hemodynamic data for all the experimental
groups is presented in Table 1. Animal body weights were
similar throughout the experimental groups and there were
no statistically significant differences in parameters that
monitor cardiac function, such as heart rate (HR), left
ventricular developed pressure (LVDP), rate pressure
product (RPP) and coronary flow prior to the induction of
regional ischaemia. In addition, none of the drugs admin-
istered at the onset of reperfusion had a statistically
significant effect on the cardiac function (data not includ-
ed). There were no significant differences in the volume of
myocardium at risk (RZ) versus the heart volume (HV)
between groups.
Metformin at reperfusion reduces myocardial infarction
but compound C given simultaneously abolishes
this protection
Metformin administered for the first 15 min of reperfusion
significantly reduced the infarct size, expressed as a
percentage of the ratio of infarct to risk volumes, when
compared to a control, vehicle treated hearts (31.4±2.9% in
metformin vs 47.8±1.7% in vehicle hearts, P<0.01; Fig. 2).
The presence of compound C, a chemical inhibitor of
AMPK [8, 16], abrogated the cardioprotective effect afforded
by metformin (42.9±2.5% in metformin+CC vs 31.4±2.9% in
metformin treated hearts, P<0.05), suggesting that the
cardioprotective effects of metformin are due to the activation
of AMPK. Of note, compound C, when given alone at the
time of reperfusion did not influence infarct size (41.5±4.5%
in CC vs 47.8±1.7% in control hearts, P = NS). DMSO
vehicle (final concentration 0.1%) did not have an effect on
infarct size when compared to control hearts perfused with
Krebs-Henseleit buffer (47.8±1.7% vs 45.9±2.32% in
control hearts, P = NS) or on AMPK phosphorylation.
AICAR, another well-known activator of AMPK [6] was
also administered either alone or in the presence of
compound C. The administration of AICAR during the
first 15 min of reperfusion significantly reduced infarct size
(32.3±4.8% in AICAR vs 47.8±1.7% in vehicle hearts P<
0.05; Fig. 3) and this effect was abolished by compound C
(47.0.3±3.0% in AICAR+CC vs. 32.3±4.8% in AICAR
treated groups, P<0.05), suggesting that AICAR protected
the cardiac tissue through the activation of AMPK.
Delayed administration of compound C does not abolish
the protective effect of metformin at reperfusion
Rat hearts were reperfused for 5 min with 50 µM of
metformin alone followed by concomitant administration of
Table 1 Hemodynamic baseline parameters. There were no significant differences between the groups regarding body weight, the hemodynamic
parameters at the end of stabilization and the ratio between risk zone and the heart volume. (CC compound C, LVDP left ventricular developed
pressure, RPP rate pressure product, CF coronary flow, RZ/HV risk zone/heart volume)
Experimental group n Body weight (g) HeartRate
(beat/min)
LVDP
(mmHg)
RPP
(mmHg/min)
CF (ml/min) RZ/HV (%)
Control 8 391.6±13 270±9 134.2±7 35,306±3,197 17.6±1.1 53.2±1.8
Vehicle 8 398.7±24 236±10 167.8±25 38,549±4,647 18.2±1.9 58.9±2.2
Metformin 10 378.7±9 273±6 133.1±11 32,642±3,929 18.8±0.9 57.3±1.2
Metformin+CC 8 347.0±14 260±31 135.3±9 30,446±5,066 19.9±2.1 49.0±2.8
Metformin+delayed CC 6 355.5±14 270±5 146.6±11 36,707±2,308 18.4±1.1 52.2±2.1
AICAR 8 373.8±6 238±8 146.6±11 36,626±4,161 17.6±2.0 49.7±1.9
AICAR+CC 7 373.5±18 250±14 108.0±12 26,235±3,482 15.8±1.2 51.3±3.5
CC 7 362.3±14 260±11 136.8±12 38,746±4,291 18.6±1.1 49.4±2.6
delayed CC 7 362.0±14 265±9 116.5±4 29,630±1,463 16.4±1.4 53.6±2.1
i baseline parameters. There w re no signifi-
c nt differences between the gr ups regarding ody weight, th
hemodynamic param ters at the end of stabilizati n and the ratio
betwe n risk zo e and the heart volume. (CC compound C, LVDP left
ventricular developed press re, RPP rate pressure p o uct, CF
coronary flow, RZ/HV risk zone/heart volume)
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metformin and compound C. Interestingly, the cardiopro-
tection aforded by metformin was not abrogated and
myocardial infarction was still significantly decreased
(28.6±2.5% in metformin with delayed CC vs 47.8±1.7%
in vehicle hearts P<0.05; Fig. 4). Delayed administration of
Compound C alone during reperfusion did not affect infarct
size (44.2±4.6% vs 47.8±1.7% in vehicle hearts P = NS).
Metformin activates AMPK when given at the onset
of reperfusion
In control hearts, α-AMPK phosphorylation significantly
increased during ischaemia (0.73±0.08 a.u. in ischaemia vs
0.17±0.02 a.u. in stabilization, P<0.05, a.u. = arbitrary
units) and did not vary significantly in the first 30 min of
reperfusion (0.73±0.08 in ischaemia vs 0.48±0.09 a.u.,
0.77±0.09 a.u., 0.60±0.17 a.u. and 0.51±0.012 a.u,, in the
samples collected at 3, 7, 15 and 30 min of reperfusion
respectively P = NS) (Fig. 5). However, the presence of
metformin, induced an increase in α-AMPK phosphoryla-
tion throughout the duration of the treatment. This value
was significantly increased for the first 3 min of reperfu-
sion, when compared to the control group (1.25±0.1 a.u. in
metformin group vs 0.48±0.09 a.u. in control group, P<
0.01) and maintained until 7 min of reperfusion (1.10±
0.08 a.u. in metformin group vs 0.77±0.09 a.u. in control
group, P<0.05). Interestingly, this increase was transitory
and slowly decreased to control values when metformin
treatment was stopped and the drug was washed out from
the tissue (0.60±0.17 a.u. in control hearts at 15 min of
reperfusion vs 0.94±0.19 a.u. in metformin treated hearts:
0.51±0.012 a.u. control hearts at 30 min of reperfusion vs
0.91±0.15 a.u. metformin treated hearts: P = NS). AMPK
phosphorylation following the administration of Compound
C has not been assessed in this study, based on the
observation that this inhibitor may work by blocking
AMPK activity rather than its phosphorylation [17].
Discussion
In the present study we demonstrated that the administra-
tion of metformin or AICAR during the first 15 min of
reperfusion provides a significant reduction of myocardial
infarction, a beneficial effect that can be abolished in the
presence of an AMPK inhibitor, compound C. Although it
has already been shown that metformin administration at
the onset of reperfusion can reduce myocardial infarction
through the activation of AMPK in several animal models
Fig. 4 A delayed administration of compound C at reperfusion does
not abolish metformin’s cardioprotective effect. Metformin’s presence
during the initial 5 min of reperfusion is sufficient to reduce
myocardial infarction. (N≥7 ★: P<0.05 compared to vehicle control
group; I/R %—infarct to risk zone volume percentage)
Fig. 3 AICAR, an AMPK activator, administered at the time of
reperfusion, reduces myocardial infarct size. However, compound C—
an AMPK inhibitor, abolishes this cardioprotective effect. (N≥7 ★:
P<0.05 compared to vehicle control group; I/R %—infarct to risk
zone volume percentage)
Fig. 2 Metformin administered at the time of reperfusion significantly
reduces myocardial infarct size. Nonetheless, compound C—an
AMPK inhibitor, abolishes this cardioprotective effect. (N≥7 ★:P<
0.05 compared to vehicle control group; I/R %—infarct to risk zone
volume percentage)
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[11, 12, 19], our results further demonstrated that this
protective effect is due to a transitory activation of AMPK
during the initial minutes of reperfusion. Thus, compound
C, when administered 5 min after the administration of
metformin at the onset of reperfusion, is not able to abolish
the protection induced by the presence of metformin.
Furthermore, we demonstrated that metformin induces an
increased activation of AMPK above control values
(assessed via phosphorylation of the Thr172 residue on
the catalytic α subunit of this kinase), when given during
the first minutes of reperfusion.
The importance of AMPK activity during ischaemia-
reperfusion injury has been extensively investigated, but the
data obtained are sometimes contradictory amongst differ-
ent groups. Russel and collaborators [20] showed that, in
the hearts of transgenic mice expressing inactive AMPKα2
kinase (the main isoform of the catalytic subunit of AMPK
found in cardiac cells) and perfused with a low concentra-
tion of fatty acids, glucose uptake and utilization were
impaired, cardiac function was decreased and cell death
markers were elevated. However, this issue is still under
debate because, using the same genetic mice model, Folmes
and colleagues [21] could not reproduce the same results
and therefore concluded that AMPK activation is not
relevant for the recovery of the cardiac tissue after
ischaemia-reperfusion injury. Further support for the im-
portance of AMPK activation in the ischaemic heart came
from the work of Shibata [22]. When using adiponectin
knockout mice that exhibited low phosphorylated levels of
alpha AMPK, high apoptotic cell death was observed
following cardiac ischaemic injury, suggesting a prosur-
vival role for AMPK during ischaemia-reperfusion injury.
The signalling pathways responsible for the cardiopro-
tective effects of acute metformin administration seem to be
very complex, including a variety of downstream cellular
targets [7]. Metformin’s acute administration at the onset of
reperfusion was shown by Legtenberg and colleagues to
significantly reduce cardiac functional loss induced by a
mild ischaemic incident (stunning) in an isolated working
rat heart model [16]. Kawabata and Ishikawa found that
acute metformin treatment improved myocardial energy
metabolism during a sustained ischaemic insult, an effect
abolished in presence of L-NAME, a non-specific nitric
oxide synthase inhibitor, implying an upregulation of nitric
oxide production by metformin as a cardioprotective
mechanism [23]. Furthermore, metformin was shown by
Calvert to protect the diabetic murine heart via activation of
AMPK and subsequent activation of endothelial nitric
oxide synthase [12]. We have also previously shown, in
cardiomyocytes exposed to laser induced oxidative stress,
that metformin is able to delay the opening of the
mitochondrial transition pore in a PI3K-dependent manner
[11]. We further demonstrated that metformin can protect
the normoglycaemic rat heart through stimulation of
adenosine receptors [13]. In addition to pharmacological
agents such as metformin and AICAR, multiple endoge-
nous ligands also work by activating AMPK such as
adiponectin, leptin, and GLP-1 [2]. Interestingly, the
aforementioned agents were also demonstrated to play a
role in the protection of cardiac cells against reperfusion
injury [22, 24, 25].
In our ex vivo study we used two different AMPK
activators that were both able to reduce infarct size:
metformin and AICAR. Metformin was demonstrated by
Zhang to increase the levels of cytosolic AMP in the heart
[26] while Zou and colleagues [27] showed that metformin
promotes the interaction between LKB1 (one of the AMPK
upstream activating kinases) and AMPK, both these effects
being essential for AMPK activation. On the other hand,
AICAR is also known to mimic an increase in the level of
AMP due to its intracellular degradation to ZMP, a
chemical analogue of AMP [6]. In addition, it was shown
by Zhang and colleagues that the same concentration of
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Fig. 5 a Representative blots for AMPK phosphorylation at the end
of stabilisation (S) and ischaemia (I) and induced by metformin during
reperfusion (3R, 7R, 15R 30R, in which the figures represent the time
point of sample collection during reperfusion (R)). β-actin blots are
included for comparing the protein levels amongst samples; b AMPK
phosphorylation calculated in arbitrary units vs. total level of AMPK.
Metformin increases AMPK phosphorylation in the early minutes of
reperfusion. -♦-Control hearts, -■-Metformin treated hearts. Values
expressed as relative density (a.u.) of the blot’s bands, calculated as
the ratio between the phosphorylated residue Thr172 of α –AMPK
and total α –AMPK , adjusted to β-actin as a loading control. (N≥3
★★: P<0.01 compared to control group for same period of collection.
★ P<0.05 compared to control group at same time point of sample
collection)
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AICAR used in our study could significantly increase
AMPK activity in a murine heart model [28]. Although the
reduction in infarct size following the administration of
metformin at the onset of reperfusion is not a novel finding,
our results contribute to further clarify the relevance of
AMPK activation during the reperfusion period. Our data
seem to point out that a transitory rather than a sustained
activation is sufficient for cardioprotection. This observa-
tion may have significant physiological implications by
avoiding the potentially excessive accumulation of glyco-
litic products. It is known that myocardial ischaemia results
in a decrease of ATP levels in the heart due to impaired
mitochondrial oxidative metabolism. Hence, during ischae-
mia, AMPK activation will be concomitant with an increase
of anaerobic glycolysis, leading to energy production and
accumulation of lactate and H+. Upon reperfusion, contrac-
tile function recovers as soon as energy levels are restored
at the expense of fatty acid oxidation. However, if AMPK is
persistently activated during reperfusion, glycolysis will be
favoured instead of pyruvate oxidation, resulting in increase
acidosis and continued decrease in cardiac efficiency during
the critical period of recovery throughout reperfusion. We
propose that, in our model, a short, reversible activation of
AMPK in the first minutes of reperfusion may protect the
heart against infarction by providing sufficient energy for
cell viability while the myocardium is still readjusting its
metabolism to the presence of oxygen. It has been shown
that postconditioning protects the heart by maintaining
acidosis during the first minutes of reperfusion, a mecha-
nism essential for keeping the mPTP closed and myocytes
viable [29]. One can assume that keeping AMPK activated
for the initial minutes of reperfusion will therefore be
sufficient to induce both transient acidosis and generate
sufficient cellular energy for cardiac work, hence protecting
the heart from reperfusion injury. However, further inves-
tigations need to be undertaken in order to clarify if this
protection is achieved via the crosstalk of prosurvival
signalling pathways with AMPK pathway and if there is
also an involvement of the metabolic changes induced by
AMPK activation. Nonetheless, all data seem to highlight
AMPK as an important cellular integrator of metabolic and
survival signalling pathways that plays a significant role in
the protection of the ischaemic-reperfused myocardium. In
our experimental model, glucose is the main metabolic
cardiac fuel. It is known that ischaemia induced—AMPK
activation enhances glucose uptake and glucose anaerobic
utilization, allowing the heart to produce sufficient ATP to
maintain cardiac function [30]. The transitory activation of
AMPK at the onset of reperfusion may be essential for the
heart to readjust from an anaerobic glucose metabolism to
the aerobic oxidative metabolism of glucose.
Our study has a number of limitations. It is know that
AICAR can induce cardioprotection through the activation
of adenosine receptors [14] but it is also known to inhibit
the Na+/H+ exchanger [31] as well as to modulate the
phosphorylation of cardioprotective kinases such as Akt
and ERK [32, 33] while metformin may have beneficial
effects in the heart independently of AMPK [34]. It is also
important to recognize that an in vitro heart model cannot
reproduce accurately the in vivo conditions of systemic
blood circulation, such as the presence of exogenous fatty
acids as energetic substrates for the myocardium. Nonethe-
less, it has been shown that fatty acid oxidation rates are
enhanced during the reperfusion period [35], leading to an
impaired recovery of cardiac function [36]. In addition,
AMPK activation in the heart has been demonstrated to
occur in response to physiological concentrations of long
chain fatty acids independently of alterations of the AMP/
ATP ratio [37]. Therefore, the introduction of fatty acids in
our experimental model would have led to an enhanced
and/or more prolonged activation of AMPK in response to
metformin at the onset of reperfusion. However, our data
have shown that a short time application of metformin at
reperfusion can be as cardioprotective as an in vivo
administration of this drug prior to an ischaemic injury.
[11, 38].
In conclusion, we report here that, in the isolated rat
heart, the transitory activation of AMPK at reperfusion
plays a significant role in the myocardial survival following
an ischaemia-reperfusion injury and that this may be one of
the mechanisms responsible for the cardioprotective effects
of metformin.
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